The ‘Global Intravenous Immunoglobulin Market Price, Size, Trends, Growth, Analysis, Key Players, Report and Forecast 2023-2028’ by Expert Market Research gives an extensive outlook of the global intravenous immunoglobulin market, assessing the market based on its segments like form, product, indication, distribution channels, end use, and major regions.
Intravenous Immunoglobulin Market Size, Trends, Industry Report, Key Player, Major Segments, and Forecast
The key highlights of the report include:
Market Overview (2017-2027)
- Forecast CAGR (2023-2028): 6.90%
|Growth Rate CAGR||6.90%|
|Major Players||CSL Limited, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd.,
Biotest AG, and LFB S.A, among others
The growth of the global intravenous immunoglobulin market has been driven by several factors including the increase in geriatric population, rise in haemophilic patients, and rapid technological advances in immunoglobulin production and purification techniques.
Get a Free Sample Report with Table of Contents- https://www.expertmarketresearch.com/reports/intravenous-immunoglobulin-market/requestsample
Moreover, the market growth rate is further anticipated to be supported by the growing incidences of various autoimmune diseases such as immune thrombocytopenia purpura (ITP), autoimmune haemolytic anaemia, multiple sclerosis, and Kawasaki syndrome, among others. There is an increasing adoption of intravenous immunoglobulin therapies as the first line of treatment for several primary immunodeficiency and other neurological and rare immunological diseases.
Further, the intravenous immunoglobulin market in the historical period was supported by the increased research and development and production by key players during the COVID-19 pandemic. For instance, in June 2020, Grifols, S.A. started production of an anti-SARS-CoV-2 hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19 which was used in the treatment and prevention of infections.
Additionally, the development of new products and mergers and acquisitions are anticipated to provide impetus to the intravenous immunoglobulin market growth in the forecast period.
Intravenous Immunoglobulin Industry Definition and Major Segments
Intravenous immunoglobulin (IVIG) therapies are used in treatment of patients with antibody deficiencies. Immunoglobulins are the glycoprotein molecules produced by the plasma or the white blood cells. These molecules are a critical part of the immune system. Immunoglobulins aid in the destruction of antigens such as viruses by recognising them and binding itself to them.
Read Full Report with Table of Contents- https://www.expertmarketresearch.com/reports/intravenous-immunoglobulin-market
On the basis of form, the market is segmented into:
Based on product, the market is categorised into:
On the basis of indication, the market is segmented into:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Guillain-Barre Syndrome
- Myasthenia Gravis
- Multifocal Motor Neuropathy (MMN)
- Kawasaki Disease
- Chronic Lymphocytic Leukaemia
Based on distribution channels, the market is categorised into:
- Hospital Pharmacies
- Retail Pharmacies
The market based on end use is segmented into:
- Home Care
On the basis of region, the market is divided into:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Intravenous Immunoglobulin Market Trends
Regionally, North America dominated the global intravenous immunoglobulin market over the historical period and is projected to continue to hold a significant share over the coming years. Factors such as presence of key market players, increasing focus on research and development of new treatments, and a developed healthcare system have aided the regional growth.
Moreover, increasing approvals for new treatments are expected to propel the intravenous immunoglobulin market growth in North America. For instance, in June 2022, the United States Food and Drug Administration (FDA) approved Amgen’s RIABNI (rituximab-arrx), a biosimilar to Rituxan. RIABNI is a combination with methotrexate indicated for adults experiencing moderate to severely active rheumatoid arthritis (RA) with an inadequate response to tumour necrosis factor (TNF) antagonist therapies.
Several pharmaceutical companies are increasingly innovating and developing immunoglobulin products for the treatment of primary immunodeficiency. In May 2021, the Biologics License Application (BLA) by GC Pharma for “GC5107 (Immune Globulin Intravenous (Human), 10% Liquid)” was accepted by the FDA. GC5107 is intended for the treatment of Primary Humoral Immunodeficiency.
Meanwhile, factors such as increasing government expenditure on healthcare in countries like India and China, increasing penetration of global players, and rising incidences of primary immunodeficiencies in the population are expected to bolster the Asia Pacific market.
Key Market Players
The major players in the intravenous immunoglobulin market report are:
- CSL Limited
- Grifols, S.A.
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Biotest AG
- LFB S.A
The report studies the latest updates in the market, along with their impact across the market. It also analyses the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.
Expert Market Research (EMR) is a leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium-scale enterprises.
EMR customises syndicated reports according to client’s requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate, and actionable industry intelligence so that they may formulate informed, effective, and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Frara Prih, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA